Perspectives on current approaches to virtual screening in drug discovery

被引:1
|
作者
Muegge, Ingo [1 ]
Bentzien, Jorg [1 ]
Ge, Yunhui [1 ]
机构
[1] Alkermes Inc, Res Dept, 900 Winter St, Waltham, MA 02451 USA
关键词
Ultra-large libraries; docking; active learning; hit finding; chemical space; DFT CALCULATIONS; INHIBITORS; DOCKING; IDENTIFICATION; LIGANDS; DESIGN; COLLECTIONS; EXPLORATION; ACCURATE; DATABASE;
D O I
10.1080/17460441.2024.2390511
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: For the past two decades, virtual screening (VS) has been an efficient hit finding approach for drug discovery. Today, billions of commercially accessible compounds are routinely screened, and many successful examples of VS have been reported. VS methods continue to evolve, including machine learning and physics-based methods. Areas covered: The authors examine recent examples of VS in drug discovery and discuss prospective hit finding results from the critical assessment of computational hit-finding experiments (CACHE) challenge. The authors also highlight the cost considerations and open-source options for conducting VS and examine chemical space coverage and library selections for VS. Expert opinion: The advancement of sophisticated VS approaches, including the use of machine learning techniques and increased computer resources as well as the ease of access to synthetically available chemical spaces, and commercial and open-source VS platforms allow for interrogating ultra-large libraries (ULL) of billions of molecules. An impressive number of prospective ULL VS campaigns have generated potent and structurally novel hits across many target classes. Nonetheless, many successful contemporary VS approaches still use considerably smaller focused libraries. This apparent dichotomy illustrates that VS is best conducted in a fit-for-purpose way choosing an appropriate chemical space. Better methods need to be developed to tackle more challenging targets.
引用
收藏
页码:1173 / 1183
页数:11
相关论文
共 50 条
  • [1] Hierarchical virtual screening approaches in small molecule drug discovery
    Kumar, Ashutosh
    Zhang, Kam Y. J.
    METHODS, 2015, 71 : 26 - 37
  • [2] Virtual Screening in Hepatitis B Virus Drug Discovery: Current State-of-the-Art and Future Perspectives
    Elmessaoudi-Idrissi, Mohcine
    Blondel, Arnaud
    Kettani, Anass
    Windisch, Marc P.
    Benjelloun, Soumaya
    Ezzikouri, Sayeh
    CURRENT MEDICINAL CHEMISTRY, 2018, 25 (23) : 2709 - 2721
  • [3] Ligand and structure-based virtual screening approaches in drug discovery: minireview
    da Rocha, Matheus Nunes
    de Sousa, Damiao Sampaio
    Mendes, Francisco Rogenio da Silva
    dos Santos, Helcio Silva
    Marinho, Gabrielle Silva
    Marinho, Marcia Machado
    Marinho, Emmanuel Silva
    MOLECULAR DIVERSITY, 2024,
  • [4] Phenotypic screening Approaches to develop Aurora Kinase Inhibitors: drug discovery Perspectives
    Marugan, Carlos
    Torres, Raquel
    Jose Lallena, Maria
    FRONTIERS IN ONCOLOGY, 2016, 5
  • [5] Virtual screening strategies in drug discovery
    McInnes, Campbell
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2007, 11 (05) : 494 - 502
  • [6] Virtual compound screening in drug discovery
    Stumpfe, Dagmar
    Ripphausen, Peter
    Bajorath, Juergen
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (05) : 593 - 602
  • [7] Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
    Bajusz, David
    Ferenczy, Gyorgy G.
    Keseru, Gyorgy M.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2017, 17 (20) : 2235 - 2259
  • [8] Integration of virtual screening into the drug discovery process
    Chin, DN
    Chuaqui, CE
    Singh, J
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (10) : 1053 - 1065
  • [9] Virtual screening in drug discovery - A computational perspective
    Reddy, A. Srinivas
    Pati, S. Priyadarshini
    Potukuchi, Praveen Kumar
    Pradeep, H. N.
    Sastry, G. Narahari
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2007, 8 (04) : 329 - 351
  • [10] The holistic integration of virtual screening in drug discovery
    Tanrikulu, Yusuf
    Krueger, Bjoern
    Proschak, Ewgenij
    DRUG DISCOVERY TODAY, 2013, 18 (7-8) : 358 - 364